Jury Bats Down Synthon’s Claim Against Pfizer

Law360, New York (August 18, 2006, 12:00 AM EDT) -- In another victory for brand name drug companies, a federal jury has rejected Dutch generics maker Synthon IP Inc.’s claim that Pfizer Inc.’s blockbuster blood pressure drug Norvasc violates its intellectual property.

Pfizer announced the ruling on Friday, adding that the jury also found Synthon’s patent invalid on multiple grounds.

“Today’s unanimous decisions underscore our determination to defend our products against unwarranted attacks and to support research-based medical innovations that benefit millions of patients,” said Allen Waxman, Pfizer’s general counsel.

Synthon IP Inc., the U.S. patent-holding...
To view the full article, register now.